Department

Dermatology

Burns, chronic wounds, skin grafts, dermatological inflammations

4 FDA-approved 1 research

HBOT Applications

FDA-Approved Level A

Chronic Non-Healing Wounds

Adjunctive HBOT for chronic non-healing wounds, including diabetic foot ulcers and vascular ulcers. Evidence base for chronic wound healing is the most robust dermatology application of HBOT.

Protocol

Pressure

2.0 – 2.5 ATA

Duration

60 – 90 min

Sessions

20 – 40

Frequency

Once daily, 5×/week

Evidence basis: UHMS / Standard of Care

References: 1 7
FDA-Approved Level A

Radiation Dermatitis & Soft-Tissue Radiation Injury

Treatment for radiation dermatitis and delayed soft-tissue healing after radiotherapy. Promotes angiogenesis in hypoxic, hypovascular, hypocellular tissue.

Protocol

Pressure

2.0 – 2.5 ATA

Duration

60 – 90 min

Sessions

20 – 40

Frequency

Once daily, 5×/week

Evidence basis: UHMS / Standard of Care

References: 1 12
FDA-Approved Level B

Compromised Skin Grafts & Flaps

Salvage adjunct for ischemic or venously congested skin grafts and flaps. Earlier initiation when perfusion issues are identified is associated with better outcomes; HBOT improves oxygen delivery, angiogenesis, fibroblast activity, and edema control.

Protocol

Pressure

2.0 – 2.5 ATA

Duration

60 – 90 min

Sessions

20 – 30

Frequency

Once daily, 5×/week

Evidence basis: UHMS / Standard of Care

References: 1 13 33
FDA-Approved Level A

Burns & Necrotizing Soft-Tissue Infection

Adjunctive treatment for necrotizing fasciitis, Fournier's gangrene, and severe burns. Reduces mortality and tissue loss when combined with surgical debridement and antibiotic therapy.

Protocol

Pressure

2.0 – 2.5 ATA

Duration

90 min

Sessions

20 – 30

Frequency

Once daily, 5×/week

Evidence basis: UHMS / Standard of Care

References: 1 10 33
Emerging Evidence Level C

Inflammatory Dermatoses

Case-level and small-cohort evidence in atopic dermatitis (2025 review + paediatric study) and psoriasis (2009 case reports). Other inflammatory conditions (hidradenitis suppurativa, livedoid vasculopathy, pyoderma gangrenosum) have early-stage clinical reports but lack robust trials. HBOT is positioned as adjunctive, not first-line.

Protocol

Pressure

2.0 – 2.8 ATA

Duration

60 – 90 min

Sessions

6 – 30 (highly variable)

Frequency

Daily, protocol-dependent

Evidence basis: Case Reports & Small Studies